Active ingredientTosedostatCat. No. P-T168-001CAS 238750-77-1Family · Pharmaceutical analytical standards
Tosedostat
An oral aminopeptidase inhibitor studied as an experimental therapy for acute myeloid leukaemia and myelodysplastic syndromes, especially in older patients; in 2008 it received orphan drug designation in the United States for acute myeloid leukaemia. This family brings together the active ingredient and nitrosamines.
Did you know?Inside cells it turns into a metabolite that can hardly get out: trapped there, it starves tumour cells of the amino acids they need to build proteins. It was originally evaluated for multiple sclerosis.
Go to the active ingredient →Active ingredientTosedostatCat. No. P-T168-001CAS 238750-77-1
NitrosamineN-Nitroso TosedostatCat. No. P-T168-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.